



NDA 22456/S005

**SUPPLEMENT APPROVAL**

Santarus, Inc  
Attention: David Truong, Pharm D., M.S.  
Manager, Regulatory Affairs  
3721 Valley Center Drive Suite 400  
San Diego, CA 92130

Dear Dr. Truong:

Please refer to your Supplemental New Drug Application (sNDA) dated March 2, 2012, and received March 5, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for (omeprazole/sodium bicarbonate/magnesium hydroxide) Tablets.

We acknowledge receipt of your amendments dated April 11, 2012 and December 3, 2012.

This Prior Approval supplemental new drug application provides for the following:

- the addition of *Clostridium difficile* associated diarrhea to the Warnings and Precautions section of the package insert
- the replacement of the patient package insert with a Medication Guide
- additional information on the interaction between omeprazole and clopidogrel to both the Warnings and Precautions and Drug Interactions sections of the package insert
- the addition of concomitant use of Zegerid with St. John's Wort or Rifampin to the Warnings and Precautions section of the package insert
- the addition of interactions with diagnostic investigations for neuroendocrine tumors in the Warnings and Precautions section of the label

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted on April 11, 2012, except with the revisions listed below, as soon as they are available, but no more than 30 days after they are printed.

Please ADD (shown with underline) the following to your Medication Guide dispensing statement: “Dispense with enclosed medication guide”

Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 21636/S-012 and NDA 21849/S-007.**” Approval of this submission by FDA is not required before the labeling is used.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Barley, Senior Regulatory Project Manager, at (301) 796-2137.

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology and Inborn Errors  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOYCE A KORVICK  
12/11/2012